Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

CYTO Altamira Therapeutics Ltd

0,30

0,00 (0,00%)

31 Jan 2025 - Geschlossen

Verzögert um 15 Minuten

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]

null

Altamira Therapeutics (NASDAQ:CYTO)
Historical Stock Chart
Von Jan 2025 bis Feb 2025

Click Here for more Altamira Therapeutics Charts.

Altamira Therapeutics (NASDAQ:CYTO)
Historical Stock Chart
Von Feb 2024 bis Feb 2025

Click Here for more Altamira Therapeutics Charts.

News Altamira Therapeutics Ltd

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Freitag 20 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
Freitag 20 Dezember 2024 (1 Monat vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Freitag 4 Oktober 2024 (4 Monate vor) • Edgar (US Regulatory)

Altamira Therapeutics Provides Update on Nasdaq Listing
Freitag 4 Oktober 2024 (4 Monate vor) • GlobeNewswire Inc.

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
Freitag 27 September 2024 (4 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 24 September 2024 (4 Monate vor) • Edgar (US Regulatory)

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
Dienstag 24 September 2024 (4 Monate vor) • GlobeNewswire Inc.

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
Freitag 20 September 2024 (4 Monate vor) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Donnerstag 19 September 2024 (4 Monate vor) • Edgar (US Regulatory)

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
Donnerstag 19 September 2024 (4 Monate vor) • GlobeNewswire Inc.

Form 424B4 - Prospectus [Rule 424(b)(4)]
Mittwoch 18 September 2024 (4 Monate vor) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Mittwoch 18 September 2024 (5 Monate vor) • Edgar (US Regulatory)

Weitere Altamira Therapeutics Ltd News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen